^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABTL0812

    i
    Other names: ABTL0812, LP-10218, ABTL-0812, SCLN-0812, α-Hydroxylinoleic acid
    Associations

    News

    Trials
    Company:
    Ability Pharma, SciClone
    Drug class:
    mTOR inhibitor, PPAR α agonist, PPAR γ agonist
    Related drugs:
    Associations

    News

    Trials
    2ms
    PanC-ASAP: ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study (clinicaltrials.gov)
    P1/2, N=150, Completed, Ability Pharmaceuticals SL | Trial completion date: Sep 2028 --> Jan 2024 | Trial primary completion date: Dec 2024 --> Jan 2024 | Recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • ABTL0812
    6ms
    PanC-ASAP: ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Ability Pharmaceuticals SL | Phase classification: P2 --> P1/2
    Phase classification • Combination therapy • Metastases
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • ABTL0812
    over1year
    Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models. (PubMed, Front Oncol)
    Finally, we investigated the combination of ABTL0812 with the standard of care treatments for GBM radiotherapy and temozolomide in an orthotopic model, detecting that ABTL0812 potentiates the efficacy of both treatments and that the strongest effect is obtained with the triple combination of ABTL0812+radiotherapy+temozolomide. Overall, the present study demonstrated the anticancer efficacy of ABTL0812 as single agent and in combination with the GBM standard of care treatments in models of glioblastoma and supports the clinical investigation of ABTL0812 as a potential novel therapy for this aggressive brain tumor type.
    Journal
    |
    TRIB3 (Tribbles Pseudokinase 3)
    |
    temozolomide • ABTL0812
    3years
    [VIRTUAL] ABTL0812, a Phase 2 clinical stage pro-autophagy anticancer drug exhibits immunomodulatory effects that modify tumor microenvironment in pancreatic cancer models (AACR 2021)
    Overall, these multiple actions could potentially help to transform “cold” non-immunogenic tumors into “hot” immunogenic tumors and contribute to elicit anticancer immunosurveillance. These novel findings support further investigation of ABTL0812 in combination with immunotherapy to treat cancer
    Clinical • P2 data • Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • GLI2 (GLI Family Zinc Finger 2) • IL1B (Interleukin 1, beta) • TRIB3 (Tribbles Pseudokinase 3)
    |
    TP53 mutation • KRAS mutation
    |
    ABTL0812
    almost4years
    [VIRTUAL] Phase II of ABTL0812, a pro-autophagic drug, in combination with paclitaxel and carboplatin (P/C) as first-line treatment in advanced/recurrent endometrial cancer (ESMO 2020)
    Funding: Ability Pharmaceuticals SL. Clinical trial identification: EudraCT: 2016-001352-21.
    Clinical • P2 data • Combination therapy
    |
    TRIB3 (Tribbles Pseudokinase 3)
    |
    carboplatin • paclitaxel • ABTL0812